Optimization of Phage-Antibiotic Combinations against Staphylococcus aureus Biofilms
The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predomin...
Saved in:
| Published in: | Microbiology spectrum Vol. 11; no. 3; p. e0491822 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
American Society for Microbiology
15.06.2023
|
| Subjects: | |
| ISSN: | 2165-0497, 2165-0497 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predominant mode of bacterial growth in nature) into consideration, as it is unclear how interactions between any specific phage and its bacterial hosts will depend on the physical properties of the growth environment.
Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are hypothesized to slow the overall development of resistance by challenging the bacteria with more than one phage. Here, we have used a combination of plate-, planktonic-, and biofilm-based screening assays to try to identify phage-antibiotic combinations that will eradicate preformed biofilms of
Staphylococcus aureus
strains that are otherwise difficult to kill. We have focused on methicillin-resistant
S aureus
(MRSA) strains and their daptomycin-nonsusceptible vancomycin-intermediate (DNS-VISA) derivatives to understand whether the phage-antibiotic interactions are altered by the changes associated with evolution from MRSA to DNS-VISA (which is known to occur in patients receiving antibiotic therapy). We evaluated the host range and cross-resistance patterns of five obligately lytic
S. aureus
myophages to select a three-phage cocktail. We screened these phages for their activity against 24-h bead biofilms and found that biofilms of two strains, D712 (DNS-VISA) and 8014 (MRSA), were the most resistant to killing by single phages. Specifically, even initial phage concentrations of 10
7
PFU per well could not prevent visible regrowth of bacteria from the treated biofilms. However, when we treated biofilms of the same two strains with phage-antibiotic combinations, we prevented bacterial regrowth when using up to 4 orders of magnitude less phage and antibiotic concentrations that were lower than our measured minimum biofilm inhibitory concentration. We did not see a consistent association between phage activity and the evolution of DNS-VISA genotypes in this small number of bacterial strains.
IMPORTANCE
The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predominant mode of bacterial growth in nature) into consideration, as it is unclear how interactions between any specific phage and its bacterial hosts will depend on the physical properties of the growth environment. In addition, the extent of bacterial sensitivity to any given phage may vary from the planktonic to the biofilm state. Therefore, phage-containing treatments targeting biofilm infections such as catheters and prosthetic joint material may not be merely based on host range characteristics. Our results open avenues to new questions regarding phage-antibiotic treatment efficiency in the eradication of topologically structured biofilm settings and the extent of eradication efficacy relative to the single agents in biofilm populations. |
|---|---|
| AbstractList | Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are hypothesized to slow the overall development of resistance by challenging the bacteria with more than one phage. Here, we have used a combination of plate-, planktonic-, and biofilm-based screening assays to try to identify phage-antibiotic combinations that will eradicate preformed biofilms of Staphylococcus aureus strains that are otherwise difficult to kill. We have focused on methicillin-resistant S aureus (MRSA) strains and their daptomycin-nonsusceptible vancomycin-intermediate (DNS-VISA) derivatives to understand whether the phage-antibiotic interactions are altered by the changes associated with evolution from MRSA to DNS-VISA (which is known to occur in patients receiving antibiotic therapy). We evaluated the host range and cross-resistance patterns of five obligately lytic S. aureus myophages to select a three-phage cocktail. We screened these phages for their activity against 24-h bead biofilms and found that biofilms of two strains, D712 (DNS-VISA) and 8014 (MRSA), were the most resistant to killing by single phages. Specifically, even initial phage concentrations of 107 PFU per well could not prevent visible regrowth of bacteria from the treated biofilms. However, when we treated biofilms of the same two strains with phage-antibiotic combinations, we prevented bacterial regrowth when using up to 4 orders of magnitude less phage and antibiotic concentrations that were lower than our measured minimum biofilm inhibitory concentration. We did not see a consistent association between phage activity and the evolution of DNS-VISA genotypes in this small number of bacterial strains. IMPORTANCE The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predominant mode of bacterial growth in nature) into consideration, as it is unclear how interactions between any specific phage and its bacterial hosts will depend on the physical properties of the growth environment. In addition, the extent of bacterial sensitivity to any given phage may vary from the planktonic to the biofilm state. Therefore, phage-containing treatments targeting biofilm infections such as catheters and prosthetic joint material may not be merely based on host range characteristics. Our results open avenues to new questions regarding phage-antibiotic treatment efficiency in the eradication of topologically structured biofilm settings and the extent of eradication efficacy relative to the single agents in biofilm populations. Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are hypothesized to slow the overall development of resistance by challenging the bacteria with more than one phage. Here, we have used a combination of plate-, planktonic-, and biofilm-based screening assays to try to identify phage-antibiotic combinations that will eradicate preformed biofilms of Staphylococcus aureus strains that are otherwise difficult to kill. We have focused on methicillin-resistant S aureus (MRSA) strains and their daptomycin-nonsusceptible vancomycin-intermediate (DNS-VISA) derivatives to understand whether the phage-antibiotic interactions are altered by the changes associated with evolution from MRSA to DNS-VISA (which is known to occur in patients receiving antibiotic therapy). We evaluated the host range and cross-resistance patterns of five obligately lytic S. aureus myophages to select a three-phage cocktail. We screened these phages for their activity against 24-h bead biofilms and found that biofilms of two strains, D712 (DNS-VISA) and 8014 (MRSA), were the most resistant to killing by single phages. Specifically, even initial phage concentrations of 107 PFU per well could not prevent visible regrowth of bacteria from the treated biofilms. However, when we treated biofilms of the same two strains with phage-antibiotic combinations, we prevented bacterial regrowth when using up to 4 orders of magnitude less phage and antibiotic concentrations that were lower than our measured minimum biofilm inhibitory concentration. We did not see a consistent association between phage activity and the evolution of DNS-VISA genotypes in this small number of bacterial strains. IMPORTANCE The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predominant mode of bacterial growth in nature) into consideration, as it is unclear how interactions between any specific phage and its bacterial hosts will depend on the physical properties of the growth environment. In addition, the extent of bacterial sensitivity to any given phage may vary from the planktonic to the biofilm state. Therefore, phage-containing treatments targeting biofilm infections such as catheters and prosthetic joint material may not be merely based on host range characteristics. Our results open avenues to new questions regarding phage-antibiotic treatment efficiency in the eradication of topologically structured biofilm settings and the extent of eradication efficacy relative to the single agents in biofilm populations.Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are hypothesized to slow the overall development of resistance by challenging the bacteria with more than one phage. Here, we have used a combination of plate-, planktonic-, and biofilm-based screening assays to try to identify phage-antibiotic combinations that will eradicate preformed biofilms of Staphylococcus aureus strains that are otherwise difficult to kill. We have focused on methicillin-resistant S aureus (MRSA) strains and their daptomycin-nonsusceptible vancomycin-intermediate (DNS-VISA) derivatives to understand whether the phage-antibiotic interactions are altered by the changes associated with evolution from MRSA to DNS-VISA (which is known to occur in patients receiving antibiotic therapy). We evaluated the host range and cross-resistance patterns of five obligately lytic S. aureus myophages to select a three-phage cocktail. We screened these phages for their activity against 24-h bead biofilms and found that biofilms of two strains, D712 (DNS-VISA) and 8014 (MRSA), were the most resistant to killing by single phages. Specifically, even initial phage concentrations of 107 PFU per well could not prevent visible regrowth of bacteria from the treated biofilms. However, when we treated biofilms of the same two strains with phage-antibiotic combinations, we prevented bacterial regrowth when using up to 4 orders of magnitude less phage and antibiotic concentrations that were lower than our measured minimum biofilm inhibitory concentration. We did not see a consistent association between phage activity and the evolution of DNS-VISA genotypes in this small number of bacterial strains. IMPORTANCE The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predominant mode of bacterial growth in nature) into consideration, as it is unclear how interactions between any specific phage and its bacterial hosts will depend on the physical properties of the growth environment. In addition, the extent of bacterial sensitivity to any given phage may vary from the planktonic to the biofilm state. Therefore, phage-containing treatments targeting biofilm infections such as catheters and prosthetic joint material may not be merely based on host range characteristics. Our results open avenues to new questions regarding phage-antibiotic treatment efficiency in the eradication of topologically structured biofilm settings and the extent of eradication efficacy relative to the single agents in biofilm populations. ABSTRACT Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are hypothesized to slow the overall development of resistance by challenging the bacteria with more than one phage. Here, we have used a combination of plate-, planktonic-, and biofilm-based screening assays to try to identify phage-antibiotic combinations that will eradicate preformed biofilms of Staphylococcus aureus strains that are otherwise difficult to kill. We have focused on methicillin-resistant S aureus (MRSA) strains and their daptomycin-nonsusceptible vancomycin-intermediate (DNS-VISA) derivatives to understand whether the phage-antibiotic interactions are altered by the changes associated with evolution from MRSA to DNS-VISA (which is known to occur in patients receiving antibiotic therapy). We evaluated the host range and cross-resistance patterns of five obligately lytic S. aureus myophages to select a three-phage cocktail. We screened these phages for their activity against 24-h bead biofilms and found that biofilms of two strains, D712 (DNS-VISA) and 8014 (MRSA), were the most resistant to killing by single phages. Specifically, even initial phage concentrations of 107 PFU per well could not prevent visible regrowth of bacteria from the treated biofilms. However, when we treated biofilms of the same two strains with phage-antibiotic combinations, we prevented bacterial regrowth when using up to 4 orders of magnitude less phage and antibiotic concentrations that were lower than our measured minimum biofilm inhibitory concentration. We did not see a consistent association between phage activity and the evolution of DNS-VISA genotypes in this small number of bacterial strains. IMPORTANCE The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predominant mode of bacterial growth in nature) into consideration, as it is unclear how interactions between any specific phage and its bacterial hosts will depend on the physical properties of the growth environment. In addition, the extent of bacterial sensitivity to any given phage may vary from the planktonic to the biofilm state. Therefore, phage-containing treatments targeting biofilm infections such as catheters and prosthetic joint material may not be merely based on host range characteristics. Our results open avenues to new questions regarding phage-antibiotic treatment efficiency in the eradication of topologically structured biofilm settings and the extent of eradication efficacy relative to the single agents in biofilm populations. Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are hypothesized to slow the overall development of resistance by challenging the bacteria with more than one phage. Here, we have used a combination of plate-, planktonic-, and biofilm-based screening assays to try to identify phage-antibiotic combinations that will eradicate preformed biofilms of Staphylococcus aureus strains that are otherwise difficult to kill. We have focused on methicillin-resistant S aureus (MRSA) strains and their daptomycin-nonsusceptible vancomycin-intermediate (DNS-VISA) derivatives to understand whether the phage-antibiotic interactions are altered by the changes associated with evolution from MRSA to DNS-VISA (which is known to occur in patients receiving antibiotic therapy). We evaluated the host range and cross-resistance patterns of five obligately lytic S. aureus myophages to select a three-phage cocktail. We screened these phages for their activity against 24-h bead biofilms and found that biofilms of two strains, D712 (DNS-VISA) and 8014 (MRSA), were the most resistant to killing by single phages. Specifically, even initial phage concentrations of 10 PFU per well could not prevent visible regrowth of bacteria from the treated biofilms. However, when we treated biofilms of the same two strains with phage-antibiotic combinations, we prevented bacterial regrowth when using up to 4 orders of magnitude less phage and antibiotic concentrations that were lower than our measured minimum biofilm inhibitory concentration. We did not see a consistent association between phage activity and the evolution of DNS-VISA genotypes in this small number of bacterial strains. The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predominant mode of bacterial growth in nature) into consideration, as it is unclear how interactions between any specific phage and its bacterial hosts will depend on the physical properties of the growth environment. In addition, the extent of bacterial sensitivity to any given phage may vary from the planktonic to the biofilm state. Therefore, phage-containing treatments targeting biofilm infections such as catheters and prosthetic joint material may not be merely based on host range characteristics. Our results open avenues to new questions regarding phage-antibiotic treatment efficiency in the eradication of topologically structured biofilm settings and the extent of eradication efficacy relative to the single agents in biofilm populations. The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predominant mode of bacterial growth in nature) into consideration, as it is unclear how interactions between any specific phage and its bacterial hosts will depend on the physical properties of the growth environment. Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are hypothesized to slow the overall development of resistance by challenging the bacteria with more than one phage. Here, we have used a combination of plate-, planktonic-, and biofilm-based screening assays to try to identify phage-antibiotic combinations that will eradicate preformed biofilms of Staphylococcus aureus strains that are otherwise difficult to kill. We have focused on methicillin-resistant S aureus (MRSA) strains and their daptomycin-nonsusceptible vancomycin-intermediate (DNS-VISA) derivatives to understand whether the phage-antibiotic interactions are altered by the changes associated with evolution from MRSA to DNS-VISA (which is known to occur in patients receiving antibiotic therapy). We evaluated the host range and cross-resistance patterns of five obligately lytic S. aureus myophages to select a three-phage cocktail. We screened these phages for their activity against 24-h bead biofilms and found that biofilms of two strains, D712 (DNS-VISA) and 8014 (MRSA), were the most resistant to killing by single phages. Specifically, even initial phage concentrations of 10 7 PFU per well could not prevent visible regrowth of bacteria from the treated biofilms. However, when we treated biofilms of the same two strains with phage-antibiotic combinations, we prevented bacterial regrowth when using up to 4 orders of magnitude less phage and antibiotic concentrations that were lower than our measured minimum biofilm inhibitory concentration. We did not see a consistent association between phage activity and the evolution of DNS-VISA genotypes in this small number of bacterial strains. IMPORTANCE The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations. While most phage cocktails are designed for the planktonic state of bacteria, it is important to take the biofilm mode of growth (the predominant mode of bacterial growth in nature) into consideration, as it is unclear how interactions between any specific phage and its bacterial hosts will depend on the physical properties of the growth environment. In addition, the extent of bacterial sensitivity to any given phage may vary from the planktonic to the biofilm state. Therefore, phage-containing treatments targeting biofilm infections such as catheters and prosthetic joint material may not be merely based on host range characteristics. Our results open avenues to new questions regarding phage-antibiotic treatment efficiency in the eradication of topologically structured biofilm settings and the extent of eradication efficacy relative to the single agents in biofilm populations. |
| Author | Kunz Coyne, Ashlan J. Lehman, Susan M. Rybak, Michael J. Stamper, Kyle C. Holger, Dana El Ghali, Amer Shah, Rahi M. Kebriaei, Razieh |
| Author_xml | – sequence: 1 givenname: Razieh surname: Kebriaei fullname: Kebriaei, Razieh organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 2 givenname: Susan M. surname: Lehman fullname: Lehman, Susan M. organization: Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA – sequence: 3 givenname: Rahi M. surname: Shah fullname: Shah, Rahi M. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 4 givenname: Kyle C. surname: Stamper fullname: Stamper, Kyle C. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 5 givenname: Ashlan J. surname: Kunz Coyne fullname: Kunz Coyne, Ashlan J. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 6 givenname: Dana surname: Holger fullname: Holger, Dana organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 7 givenname: Amer surname: El Ghali fullname: El Ghali, Amer organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA – sequence: 8 givenname: Michael J. orcidid: 0000-0003-2220-0081 surname: Rybak fullname: Rybak, Michael J. organization: Anti-Infective Research Laboratory, College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA, School of Medicine, Wayne State University, Detroit, Michigan, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37199616$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kU9v1DAQxSNURP_QD8AF7ZFLFtuJnfiEygpopUpFopytiTPe9Sqxg-0glU-Pd7eLWiQ4jT3z5qdnv_PixHmHRfGGkiWlrH0fJ9QpzOOS1JK2JWMvijNGBS_zvTl5cj4tLmPcEkIoJZxx9qo4rRoqpaDirLi_m5Id7S9I1ruFN4uvG1hjeeWS7axPVi9Wfuys28_jAtZgXUyLbwmmzcPgtdd6zu05YC4frTd2GOPr4qWBIeLlY70ovn_-dL-6Lm_vvtysrm5L4ISnUlayqzXvgXMmaNcBoNTCNKYXooLaCKlNowlI1AY6kA2tekTg0AowKOrqorg5cHsPWzUFO0J4UB6s2jd8WCsI-Q0DqrxBsSFMctR1U2NXkapnwFoiatkSllkfDqxp7kbsNboUYHgGfT5xdqPW_qeihAnZyB3h3SMh-B8zxqRGGzUOAzj0c1SspZzVLa-rLF0epBBHprZ-Di7_U0apXbTqGK3aR6vYjv32qbs_to5BZkFzEOjgYwxolLZpH1o2a4f_oulfm0f4v3d-A5TBybc |
| CitedBy_id | crossref_primary_10_1007_s00705_025_06370_x crossref_primary_10_1093_jambio_lxaf081 crossref_primary_10_1007_s00253_025_13526_x crossref_primary_10_1016_j_micres_2024_128040 crossref_primary_10_1007_s00408_024_00700_7 crossref_primary_10_1128_aac_01388_23 crossref_primary_10_1186_s40001_025_02781_3 crossref_primary_10_3389_fmicb_2023_1277178 crossref_primary_10_1371_journal_pbio_3003065 crossref_primary_10_1002_jor_70029 crossref_primary_10_1128_spectrum_03212_23 crossref_primary_10_1093_femsle_fnae072 crossref_primary_10_1016_j_micinf_2025_105531 crossref_primary_10_1016_j_idc_2025_02_009 crossref_primary_10_1128_spectrum_00427_24 crossref_primary_10_1007_s00210_025_04345_y crossref_primary_10_3390_antibiotics13090870 crossref_primary_10_3390_microorganisms11092352 crossref_primary_10_3390_microorganisms11092230 crossref_primary_10_1089_fpd_2024_0130 crossref_primary_10_3390_bioengineering12050469 crossref_primary_10_1016_j_azn_2024_11_003 crossref_primary_10_1016_j_jinf_2024_106125 crossref_primary_10_3390_antibiotics12091423 crossref_primary_10_1128_spectrum_00679_24 crossref_primary_10_1128_aac_00448_24 |
| Cites_doi | 10.3390/v12020133 10.15252/embj.2021109247 10.3390/v7082845 10.1016/j.ebiom.2022.104045 10.1111/1469-0691.12651 10.1093/cid/cir153 10.3934/microbiol.2017.2.186 10.1128/genomeA.01173-13 10.3390/v10070351 10.1128/JB.186.9.2862-2871.2004 10.3390/v15010017 10.1128/AEM.00209-19 10.1177/003335490712200205 10.3390/antibiotics11070839 10.3390/v11010088 10.1111/j.1574-695X.2012.00977.x 10.1128/JVI.02763-12 10.7150/ijbs.60551 10.3390/v4050663 10.1128/aac.02071-21 10.3389/fmicb.2016.00825 10.1038/d41586-022-00228-x 10.1128/JCM.37.6.1771-1776.1999 10.1128/spectrum.00411-22 10.1038/nrmicro2315 10.1371/journal.pone.0000799 10.1038/s41467-022-33294-w 10.3390/antibiotics7020037 10.1128/AAC.01863-20 10.3390/antibiotics9050268 10.1007/978-1-4939-0473-0_48 10.3390/ph8030559 10.2217/fmb.13.47 10.1128/AEM.01209-19 10.1016/j.ajpath.2020.02.007 10.1128/AEM.02085-18 10.2174/138920108785161604 10.1128/AEM.01789-14 10.1007/s00248-007-9361-8 10.3389/fmicb.2017.00981 10.1093/femsle/fnv246 10.4161/bact.1.2.14590 10.1016/j.ijantimicag.2018.09.006 10.1111/j.1472-765X.2012.03205.x 10.1111/j.1751-7915.2011.00259.x 10.1128/AAC.00461-20 10.1093/infdis/116.4.523 |
| ContentType | Journal Article |
| Copyright | Copyright © 2023 Kebriaei et al. Copyright © 2023 Kebriaei et al. 2023 Kebriaei et al. |
| Copyright_xml | – notice: Copyright © 2023 Kebriaei et al. – notice: Copyright © 2023 Kebriaei et al. 2023 Kebriaei et al. |
| DBID | AAYXX CITATION NPM 7X8 5PM DOA |
| DOI | 10.1128/spectrum.04918-22 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed CrossRef |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 2165-0497 |
| Editor | Conlon, Brian |
| Editor_xml | – sequence: 1 givenname: Brian surname: Conlon fullname: Conlon, Brian |
| ExternalDocumentID | oai_doaj_org_article_6af1e70295ec474eb303d2a280649802 PMC10269792 04918-22 37199616 10_1128_spectrum_04918_22 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: HHS | National Institutes of Health (NIH) grantid: AI163726 – fundername: HHS | National Institutes of Health (NIH) grantid: AI121400 – fundername: HHS | National Institutes of Health (NIH) grantid: AI130056 – fundername: HHS | National Institutes of Health (NIH) grantid: AI121400 funderid: https://doi.org/10.13039/100000002 – fundername: HHS | National Institutes of Health (NIH) grantid: AI130056 funderid: https://doi.org/10.13039/100000002 – fundername: HHS | National Institutes of Health (NIH) grantid: AI163726 funderid: https://doi.org/10.13039/100000002 – fundername: ; grantid: AI130056 – fundername: ; grantid: AI163726 – fundername: ; grantid: AI121400 |
| GroupedDBID | 53G AAGFI AAUOK AAYXX ADBBV ALMA_UNASSIGNED_HOLDINGS CITATION EJD FF~ FRP GROUPED_DOAJ H13 M~E OK1 RPM RSF AGVNZ NPM EBS UCJ 7X8 5PM |
| ID | FETCH-LOGICAL-a505t-939b4c5da55261bbaae9c6f7fd663a4f69cf7c0a9ecfaba9713deea5a86afe643 |
| IEDL.DBID | DOA |
| ISICitedReferencesCount | 31 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000990229400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 2165-0497 |
| IngestDate | Fri Oct 03 12:51:03 EDT 2025 Tue Sep 30 17:13:22 EDT 2025 Thu Sep 04 14:21:14 EDT 2025 Thu May 18 22:13:15 EDT 2023 Thu Apr 03 07:13:22 EDT 2025 Sat Nov 29 01:47:46 EST 2025 Tue Nov 18 21:48:50 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Keywords | biofilms MRSA bacteriophages |
| Language | English |
| License | This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. https://creativecommons.org/licenses/by/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a505t-939b4c5da55261bbaae9c6f7fd663a4f69cf7c0a9ecfaba9713deea5a86afe643 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Present address: Razieh Kebriaei, P3 Research Laboratory, Division of Outcomes and Translational Sciences, College of Pharmacy, Ohio State University, Columbus, Ohio, USA. The authors declare no conflict of interest. |
| ORCID | 0000-0003-2220-0081 |
| OpenAccessLink | https://doaj.org/article/6af1e70295ec474eb303d2a280649802 |
| PMID | 37199616 |
| PQID | 2815248543 |
| PQPubID | 23479 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_6af1e70295ec474eb303d2a280649802 pubmedcentral_primary_oai_pubmedcentral_nih_gov_10269792 proquest_miscellaneous_2815248543 asm2_journals_10_1128_spectrum_04918_22 pubmed_primary_37199616 crossref_citationtrail_10_1128_spectrum_04918_22 crossref_primary_10_1128_spectrum_04918_22 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-Jun-15 |
| PublicationDateYYYYMMDD | 2023-06-15 |
| PublicationDate_xml | – month: 06 year: 2023 text: 2023-Jun-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
| PublicationTitle | Microbiology spectrum |
| PublicationTitleAbbrev | Microbiol Spectr |
| PublicationTitleAlternate | Microbiol Spectr |
| PublicationYear | 2023 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | e_1_3_3_17_2 e_1_3_3_16_2 e_1_3_3_19_2 e_1_3_3_38_2 e_1_3_3_18_2 e_1_3_3_39_2 e_1_3_3_13_2 e_1_3_3_36_2 e_1_3_3_12_2 e_1_3_3_37_2 e_1_3_3_15_2 e_1_3_3_34_2 e_1_3_3_14_2 e_1_3_3_35_2 e_1_3_3_32_2 e_1_3_3_33_2 e_1_3_3_11_2 e_1_3_3_30_2 e_1_3_3_10_2 e_1_3_3_31_2 Clinical and Laboratory Standards Institute (e_1_3_3_48_2) 2020 e_1_3_3_40_2 e_1_3_3_6_2 e_1_3_3_5_2 e_1_3_3_8_2 e_1_3_3_7_2 e_1_3_3_28_2 e_1_3_3_9_2 e_1_3_3_27_2 e_1_3_3_49_2 e_1_3_3_29_2 e_1_3_3_24_2 e_1_3_3_47_2 e_1_3_3_23_2 e_1_3_3_26_2 e_1_3_3_45_2 e_1_3_3_25_2 e_1_3_3_46_2 e_1_3_3_2_2 e_1_3_3_20_2 e_1_3_3_43_2 e_1_3_3_44_2 e_1_3_3_4_2 e_1_3_3_22_2 e_1_3_3_41_2 e_1_3_3_3_2 e_1_3_3_21_2 e_1_3_3_42_2 Alves, DR, Gaudion, A, Bean, JE, Perez Esteban, P, Arnot, TC, Harper, DR, Kot, W, Hansen, LH, Enright, MC, Jenkins, ATA (B16) 2014; 80 Tkhilaishvili, T, Lombardi, L, Klatt, A-B, Trampuz, A, Di Luca, M (B24) 2018; 52 Li, X, He, Y, Wang, Z, Wei, J, Hu, T, Si, J, Tao, G, Zhang, L, Xie, L, Abdalla, AE, Wang, G, Li, Y, Teng, T (B9) 2021; 17 Lehman, SM, Mearns, G, Rankin, D, Cole, RA, Smrekar, F, Branston, SD, Morales, S (B14) 2019; 11 Loc-Carrillo, C, Abedon, ST (B28) 2011; 1 Kvachadze, L, Balarjishvili, N, Meskhi, T, Tevdoradze, E, Skhirtladze, N, Pataridze, T, Adamia, R, Topuria, T, Kutter, E, Rohde, C, Kutateladze, M (B41) 2011; 4 Gill, JJ (B40) 2014; 2 Sergueev, KV, Filippov, AA, Farlow, J, Su, W, Kvachadze, L, Balarjishvili, N, Kutateladze, M, Nikolich, MP (B44) 2019; 85 Klevens, RM, Edwards, JR, Richards, CL, Horan, TC, Gaynes, RP, Pollock, DA, Cardo, DM (B1) 2007; 122 Moller, AG, Lindsay, JA, Read, TD (B19) 2019; 85 Thompson, T (B3) 2022 Chan, BK, Abedon, ST, Loc-Carrillo, C (B6) 2013; 8 Romaní, AM, Fund, K, Artigas, J, Schwartz, T, Sabater, S, Obst, U (B34) 2008; 56 (B47) 2020 Abedon, ST (B33) 2016; 363 Abedon, ST (B22) 2012; 4 Kebriaei, R, Lev, KL, Stamper, KC, Lehman, SM, Morales, S, Rybak, MJ (B38) 2020; 65 Kelly, D, McAuliffe, O, Ross, RP, Coffey, A (B20) 2012; 54 Oduor, JMO, Kadija, E, Nyachieo, A, Mureithi, MW, Skurnik, M (B42) 2020; 12 Ryan, EM, Alkawareek, MY, Donnelly, RF, Gilmore, BF (B35) 2012; 65 Comeau, AM, Tétart, F, Trojet, SN, Prère, M-F, Krisch, HM (B36) 2007; 2 Hofstee, MI, Muthukrishnan, G, Atkins, GJ, Riool, M, Thompson, K, Morgenstern, M, Stoddart, MJ, Richards, RG, Zaat, SAJ, Moriarty, TF (B26) 2020; 190 Kim, M, Jo, Y, Hwang, YJ, Hong, HW, Hong, SS, Park, K, Myung, H (B37) 2018; 84 Oechslin, F (B7) 2018; 10 Majewska, J, Beta, W, Lecion, D, Hodyra-Stefaniak, K, Kłopot, A, Kaźmierczak, Z, Miernikiewicz, P, Piotrowicz, A, Ciekot, J, Owczarek, B, Kopciuch, A, Wojtyna, K, Harhala, M, Mąkosa, M, Dąbrowska, K (B29) 2015; 7 Guidos, RJ (B2) 2011; 52 Gutiérrez, D, Rodríguez-Rubio, L, Martínez, B, Rodríguez, A, García, P (B25) 2016; 7 Suh, GA, Lodise, TP, Tamma, PD, Knisely, JM, Alexander, J, Aslam, S, Barton, KD, Bizzell, E, Totten, KMC, Campbell, JL, Chan, BK, Cunningham, SA, Goodman, KE, Greenwood-Quaintance, KE, Harris, AD, Hesse, S, Maresso, A, Nussenblatt, V, Pride, D, Rybak, MJ, Sund, Z, van Duin, D, Van Tyne, D, Patel, R (B4) 2022; 66 Azeredo, J, Sutherland, IW (B23) 2008; 9 Coffey, BM, Anderson, GG, Filloux, A, Ramos, J-L (B48) 2014 Altamirano, FLG, Kostoulias, X, Subedi, D, Korneev, D, Peleg, AY, Barr, JJ (B13) 2022; 80 Wolochow, H, Hildebrand, GJ, Lamanna, C (B30) 1966; 116 Ceri, H, Olson, ME, Stremick, C, Read, RR, Morck, D, Buret, A (B45) 1999; 37 Tzipilevich, E, Pollak-Fiyaksel, O, Shraiteh, B, Ben-Yehuda, S (B15) 2022; 41 Abedon, ST (B21) 2015; 8 Lehman, SM, Kongari, R, Glass, AM, Koert, M, Ray, MD, Plaut, RD, Stibitz, S (B18) 2022; 15 Abedon, ST, García, P, Mullany, P, Aminov, R (B31) 2017; 8 Kebriaei, R, Lev, KL, Shah, RM, Stamper, KC, Holger, DJ, Morrisette, T, Kunz Coyne, AJ, Lehman, SM, Rybak, MJ (B8) 2022; 10 Ajuebor, J, Buttimer, C, Arroyo-Moreno, S, Chanishvili, N, Gabriel, EM, O’Mahony, J, McAuliffe, O, Neve, H, Franz, C, Coffey, A (B17) 2018; 7 Vandersteegen, K, Kropinski, AM, Nash, JHE, Noben, J-P, Hermans, K, Lavigne, R (B43) 2013; 87 Van Nieuwenhuyse, B, Van der Linden, D, Chatzis, O, Lood, C, Wagemans, J, Lavigne, R, Schroven, K, Paeshuyse, J, de Magnée, C, Sokal, E, Stéphenne, X, Scheers, I, Rodriguez-Villalobos, H, Djebara, S, Merabishvili, M, Soentjens, P, Pirnay, J-P (B12) 2022; 13 Kebriaei, R, Lev, K, Morrisette, T, Stamper, KC, Abdul-Mutakabbir, JC, Lehman, SM, Morales, S, Rybak, MJ (B11) 2020; 64 O'Flaherty, S, Coffey, A, Edwards, R, Meaney, W, Fitzgerald, GF, Ross, RP (B39) 2004; 186 Ferriol-González, C, Domingo-Calap, P (B32) 2020; 9 Labrie, SJ, Samson, JE, Moineau, S (B5) 2010; 8 Macià, MD, Rojo-Molinero, E, Oliver, A (B46) 2014; 20 Diallo, K, Dublanchet, A (B10) 2022; 11 Abedon, ST (B27) 2017; 3 |
| References_xml | – ident: e_1_3_3_43_2 doi: 10.3390/v12020133 – ident: e_1_3_3_16_2 doi: 10.15252/embj.2021109247 – ident: e_1_3_3_30_2 doi: 10.3390/v7082845 – ident: e_1_3_3_14_2 doi: 10.1016/j.ebiom.2022.104045 – ident: e_1_3_3_47_2 doi: 10.1111/1469-0691.12651 – ident: e_1_3_3_3_2 doi: 10.1093/cid/cir153 – ident: e_1_3_3_28_2 doi: 10.3934/microbiol.2017.2.186 – ident: e_1_3_3_41_2 doi: 10.1128/genomeA.01173-13 – ident: e_1_3_3_8_2 doi: 10.3390/v10070351 – ident: e_1_3_3_40_2 doi: 10.1128/JB.186.9.2862-2871.2004 – ident: e_1_3_3_19_2 doi: 10.3390/v15010017 – ident: e_1_3_3_20_2 doi: 10.1128/AEM.00209-19 – ident: e_1_3_3_2_2 doi: 10.1177/003335490712200205 – ident: e_1_3_3_11_2 doi: 10.3390/antibiotics11070839 – ident: e_1_3_3_15_2 doi: 10.3390/v11010088 – ident: e_1_3_3_36_2 doi: 10.1111/j.1574-695X.2012.00977.x – ident: e_1_3_3_44_2 doi: 10.1128/JVI.02763-12 – ident: e_1_3_3_10_2 doi: 10.7150/ijbs.60551 – ident: e_1_3_3_23_2 doi: 10.3390/v4050663 – ident: e_1_3_3_5_2 doi: 10.1128/aac.02071-21 – ident: e_1_3_3_26_2 doi: 10.3389/fmicb.2016.00825 – ident: e_1_3_3_4_2 doi: 10.1038/d41586-022-00228-x – ident: e_1_3_3_46_2 doi: 10.1128/JCM.37.6.1771-1776.1999 – ident: e_1_3_3_9_2 doi: 10.1128/spectrum.00411-22 – ident: e_1_3_3_6_2 doi: 10.1038/nrmicro2315 – ident: e_1_3_3_37_2 doi: 10.1371/journal.pone.0000799 – ident: e_1_3_3_13_2 doi: 10.1038/s41467-022-33294-w – ident: e_1_3_3_18_2 doi: 10.3390/antibiotics7020037 – ident: e_1_3_3_39_2 doi: 10.1128/AAC.01863-20 – ident: e_1_3_3_33_2 doi: 10.3390/antibiotics9050268 – ident: e_1_3_3_49_2 doi: 10.1007/978-1-4939-0473-0_48 – ident: e_1_3_3_22_2 doi: 10.3390/ph8030559 – volume-title: Performance standards for antimicrobial susceptibility testing year: 2020 ident: e_1_3_3_48_2 – ident: e_1_3_3_7_2 doi: 10.2217/fmb.13.47 – ident: e_1_3_3_45_2 doi: 10.1128/AEM.01209-19 – ident: e_1_3_3_27_2 doi: 10.1016/j.ajpath.2020.02.007 – ident: e_1_3_3_38_2 doi: 10.1128/AEM.02085-18 – ident: e_1_3_3_24_2 doi: 10.2174/138920108785161604 – ident: e_1_3_3_17_2 doi: 10.1128/AEM.01789-14 – ident: e_1_3_3_35_2 doi: 10.1007/s00248-007-9361-8 – ident: e_1_3_3_32_2 doi: 10.3389/fmicb.2017.00981 – ident: e_1_3_3_34_2 doi: 10.1093/femsle/fnv246 – ident: e_1_3_3_29_2 doi: 10.4161/bact.1.2.14590 – ident: e_1_3_3_25_2 doi: 10.1016/j.ijantimicag.2018.09.006 – ident: e_1_3_3_21_2 doi: 10.1111/j.1472-765X.2012.03205.x – ident: e_1_3_3_42_2 doi: 10.1111/j.1751-7915.2011.00259.x – ident: e_1_3_3_12_2 doi: 10.1128/AAC.00461-20 – ident: e_1_3_3_31_2 doi: 10.1093/infdis/116.4.523 – volume: 8 start-page: 317 year: 2010 end-page: 327 ident: B5 article-title: Bacteriophage resistance mechanisms publication-title: Nat Rev Microbiol doi: 10.1038/nrmicro2315 – volume: 9 start-page: 268 year: 2020 ident: B32 article-title: Phages for biofilm removal publication-title: Antibiotics (Basel) doi: 10.3390/antibiotics9050268 – volume: 186 start-page: 2862 year: 2004 end-page: 2871 ident: B39 article-title: Genome of staphylococcal phage K: a new lineage of Myoviridae infecting Gram-positive bacteria with a low G+C content publication-title: J Bacteriol doi: 10.1128/JB.186.9.2862-2871.2004 – year: 2020 ident: B47 publication-title: Performance standards for antimicrobial susceptibility testing ;30th ed ;M100. ;Clinical and Laboratory Standards Institute ;Wayne, PA – volume: 64 year: 2020 ident: B11 article-title: Bacteriophage-antibiotic combination strategy: an alternative against methicillin-resistant phenotypes of Staphylococcus aureus publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.00461-20 – volume: 52 start-page: S397 year: 2011 end-page: S428 ident: B2 article-title: Combating antimicrobial resistance: policy recommendations to save lives publication-title: Clin Infect Dis doi: 10.1093/cid/cir153 – volume: 363 start-page: fnv246 year: 2016 ident: B33 article-title: Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets? publication-title: FEMS Microbiol Lett doi: 10.1093/femsle/fnv246 – volume: 7 start-page: 4783 year: 2015 end-page: 4799 ident: B29 article-title: Oral application of T4 phage induces weak antibody production in the gut and in the blood publication-title: Viruses doi: 10.3390/v7082845 – volume: 116 start-page: 523 year: 1966 end-page: 528 ident: B30 article-title: Translocation of microorganisms across the intestinal wall of the rat: effect of microbial size and concentration publication-title: J Infect Dis doi: 10.1093/infdis/116.4.523 – volume: 17 start-page: 3573 year: 2021 end-page: 3582 ident: B9 article-title: A combination therapy of phages and antibiotics: two is better than one publication-title: Int J Biol Sci doi: 10.7150/ijbs.60551 – volume: 87 start-page: 3237 year: 2013 end-page: 3247 ident: B43 article-title: Romulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applications publication-title: J Virol doi: 10.1128/JVI.02763-12 – volume: 85 year: 2019 ident: B44 article-title: Correlation of host range expansion of therapeutic bacteriophage Sb-1 with allele state at a hypervariable repeat locus publication-title: Appl Environ Microbiol doi: 10.1128/AEM.01209-19 – volume: 8 start-page: 769 year: 2013 end-page: 783 ident: B6 article-title: Phage cocktails and the future of phage therapy publication-title: Future Microbiol doi: 10.2217/fmb.13.47 – volume: 65 year: 2020 ident: B38 article-title: Bacteriophage AB-SA01 cocktail in combination with antibiotics against MRSA-VISA strain in an in vitro pharmacokinetic/pharmacodynamic model publication-title: Antimicrob Agents Chemother doi: 10.1128/AAC.01863-20 – volume: 52 start-page: 842 year: 2018 end-page: 853 ident: B24 article-title: Bacteriophage Sb-1 enhances antibiotic activity against biofilm, degrades exopolysaccharide matrix and targets persisters of Staphylococcus aureus publication-title: Int J Antimicrob Agents doi: 10.1016/j.ijantimicag.2018.09.006 – volume: 10 year: 2022 ident: B8 article-title: Eradication of biofilm-mediated methicillin-resistant Staphylococcus aureus infections in vitro: bacteriophage-antibiotic combination publication-title: Microbiol Spectr doi: 10.1128/spectrum.00411-22 – volume: 41 year: 2022 ident: B15 article-title: Bacteria elicit a phage tolerance response subsequent to infection of their neighbors publication-title: EMBO J doi: 10.15252/embj.2021109247 – volume: 85 year: 2019 ident: B19 article-title: Determinants of phage host range in Staphylococcus species publication-title: Appl Environ Microbiol doi: 10.1128/AEM.00209-19 – volume: 15 start-page: 17 year: 2022 ident: B18 article-title: Phage K gp102 drives temperature-sensitive antibacterial activity on USA300 MRSA publication-title: Viruses doi: 10.3390/v15010017 – volume: 20 start-page: 981 year: 2014 end-page: 990 ident: B46 article-title: Antimicrobial susceptibility testing in biofilm-growing bacteria publication-title: Clin Microbiol Infect doi: 10.1111/1469-0691.12651 – volume: 1 start-page: 111 year: 2011 end-page: 114 ident: B28 article-title: Pros and cons of phage therapy publication-title: Bacteriophage doi: 10.4161/bact.1.2.14590 – start-page: 631 year: 2014 end-page: 641 ident: B48 article-title: Biofilm formation in the 96-well microtiter plate publication-title: Pseudomonas methods and protocols. ;Springer ;New York, NY – volume: 190 start-page: 1151 year: 2020 end-page: 1163 ident: B26 article-title: Current concepts of osteomyelitis: from pathologic mechanisms to advanced research methods publication-title: Am J Pathol doi: 10.1016/j.ajpath.2020.02.007 – volume: 7 start-page: 37 year: 2018 ident: B17 article-title: Comparison of Staphylococcus phage K with close phage relatives commonly employed in phage therapeutics publication-title: Antibiotics doi: 10.3390/antibiotics7020037 – volume: 56 start-page: 427 year: 2008 end-page: 436 ident: B34 article-title: Relevance of polymeric matrix enzymes during biofilm formation publication-title: Microb Ecol doi: 10.1007/s00248-007-9361-8 – year: 2022 ident: B3 article-title: The staggering death toll of drug-resistant bacteria publication-title: Nature doi: 10.1038/d41586-022-00228-x – volume: 11 start-page: 839 year: 2022 ident: B10 article-title: Benefits of combined phage–antibiotic therapy for the control of antibiotic-resistant bacteria: a literature review publication-title: Antibiotics (Basel) doi: 10.3390/antibiotics11070839 – volume: 122 start-page: 160 year: 2007 end-page: 166 ident: B1 article-title: Estimating health care-associated infections and deaths in U.S. hospitals, 2002 publication-title: Public Health Rep doi: 10.1177/003335490712200205 – volume: 65 start-page: 395 year: 2012 end-page: 398 ident: B35 article-title: Synergistic phage-antibiotic combinations for the control of Escherichia coli biofilms in vitro publication-title: FEMS Immunol Med Microbiol doi: 10.1111/j.1574-695X.2012.00977.x – volume: 80 start-page: 6694 year: 2014 end-page: 6703 ident: B16 article-title: Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation publication-title: Appl Environ Microbiol doi: 10.1128/AEM.01789-14 – volume: 13 start-page: 5725 year: 2022 ident: B12 article-title: Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler publication-title: Nat Commun doi: 10.1038/s41467-022-33294-w – volume: 12 start-page: 133 year: 2020 ident: B42 article-title: Bioprospecting Staphylococcus phages with therapeutic and bio-control potential publication-title: Viruses doi: 10.3390/v12020133 – volume: 2 year: 2007 ident: B36 article-title: Phage-antibiotic synergy (PAS): beta-lactam and quinolone antibiotics stimulate virulent phage growth publication-title: PLoS One doi: 10.1371/journal.pone.0000799 – volume: 3 start-page: 186 year: 2017 end-page: 226 ident: B27 article-title: Phage “delay” towards enhancing bacterial escape from biofilms: a more comprehensive way of viewing resistance to bacteriophages publication-title: AIMS Microbiol doi: 10.3934/microbiol.2017.2.186 – volume: 4 start-page: 663 year: 2012 end-page: 687 ident: B22 article-title: Spatial vulnerability: bacterial arrangements, microcolonies, and biofilms as responses to low rather than high phage densities publication-title: Viruses doi: 10.3390/v4050663 – volume: 80 start-page: 104045 year: 2022 ident: B13 article-title: Phage-antibiotic combination is a superior treatment against Acinetobacter baumannii in a preclinical study publication-title: eBioMedicine doi: 10.1016/j.ebiom.2022.104045 – volume: 10 start-page: 351 year: 2018 ident: B7 article-title: Resistance development to bacteriophages occurring during bacteriophage therapy publication-title: Viruses doi: 10.3390/v10070351 – volume: 11 start-page: 88 year: 2019 ident: B14 article-title: Design and preclinical development of a phage product for the treatment of antibiotic-resistant Staphylococcus aureus infections publication-title: Viruses doi: 10.3390/v11010088 – volume: 9 start-page: 261 year: 2008 end-page: 266 ident: B23 article-title: The use of phages for the removal of infectious biofilms publication-title: Curr Pharm Biotechnol doi: 10.2174/138920108785161604 – volume: 54 start-page: 286 year: 2012 end-page: 291 ident: B20 article-title: Prevention of Staphylococcus aureus biofilm formation and reduction in established biofilm density using a combination of phage K and modified derivatives publication-title: Lett Appl Microbiol doi: 10.1111/j.1472-765X.2012.03205.x – volume: 7 start-page: 825 year: 2016 ident: B25 article-title: Bacteriophages as weapons against bacterial biofilms in the food industry publication-title: Front Microbiol doi: 10.3389/fmicb.2016.00825 – volume: 66 year: 2022 ident: B4 article-title: Considerations for the use of phage therapy in clinical practice publication-title: Antimicrob Agents Chemother doi: 10.1128/aac.02071-21 – volume: 2 year: 2014 ident: B40 article-title: Revised genome sequence of Staphylococcus aureus bacteriophage K publication-title: Genome Announc doi: 10.1128/genomeA.01173-13 – volume: 4 start-page: 643 year: 2011 end-page: 650 ident: B41 article-title: Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens publication-title: Microb Biotechnol doi: 10.1111/j.1751-7915.2011.00259.x – volume: 8 start-page: 559 year: 2015 end-page: 589 ident: B21 article-title: Ecology of anti-biofilm agents II: bacteriophage exploitation and biocontrol of biofilm bacteria publication-title: Pharmaceuticals (Basel) doi: 10.3390/ph8030559 – volume: 84 year: 2018 ident: B37 article-title: Phage-antibiotic synergy via delayed lysis publication-title: Appl Environ Microbiol doi: 10.1128/AEM.02085-18 – volume: 37 start-page: 1771 year: 1999 end-page: 1776 ident: B45 article-title: The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms publication-title: J Clin Microbiol doi: 10.1128/JCM.37.6.1771-1776.1999 – volume: 8 start-page: 981 year: 2017 ident: B31 article-title: Editorial: phage therapy: past, present and future publication-title: Front Microbiol doi: 10.3389/fmicb.2017.00981 |
| SSID | ssj0001105252 |
| Score | 2.4147248 |
| Snippet | The extracellular polymeric matrix of biofilms presents an impediment to antibiotic diffusion, facilitating the emergence of multidrug-resistant populations.... Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are... ABSTRACT Phage therapy has gained attention due to the spread of antibiotic-resistant bacteria and narrow pipeline of novel antibiotics. Phage cocktails are... |
| SourceID | doaj pubmedcentral proquest asm2 pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | e0491822 |
| SubjectTerms | Antimicrobial Chemotherapy bacteriophages biofilms MRSA Research Article |
| Title | Optimization of Phage-Antibiotic Combinations against Staphylococcus aureus Biofilms |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37199616 https://journals.asm.org/doi/10.1128/spectrum.04918-22 https://www.proquest.com/docview/2815248543 https://pubmed.ncbi.nlm.nih.gov/PMC10269792 https://doaj.org/article/6af1e70295ec474eb303d2a280649802 |
| Volume | 11 |
| WOSCitedRecordID | wos000990229400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2165-0497 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105252 issn: 2165-0497 databaseCode: DOA dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2165-0497 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0001105252 issn: 2165-0497 databaseCode: M~E dateStart: 20130101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3di9QwEB_0UPBF_L76cVQQBKFemyZN8njKHT7oeQ-n7FuY5sNbuG1leyv44t_uJO0uuyLniy8ttEkbJjPJb5LJbwBeMSaDE4GU1_K24LIsC4WuLgQSvGAeQ0hLF18_ytNTNZvps61UXzEmbKQHHgV32GCovCyZFt5yycn3K2vHMG4Icq1GGklCPVvOVFpdqWJ-NjZtY9IYfJgOLi5Xi7cEiStSjki8h8OC7cxHibb_b1jzz5DJrTno5B7cncBjfjQ2-j7c8N0DuD2mk_z5EM4_k_0vpoOVeR_yswsaLYqjLp4L6alOTtZPnvC4SJfjN5wTOMwJb5KsaVLrrV3R49XS042-GuaXi-ERfDk5Pn__oZiyJhRIaOaq0LVuuRUOhSDvqG0RvbZNoC4hcIE8NNoGaUvU3gZsUZOX6rxHgYpE7QmgPIa9ru_8PuQMSye0c7VVjgwdUSETKpRoI62ZExm8jiI0k9oPJnkUTJm1sE0StmEsg3ItZWMn8vGYA-PyuipvNlW-j8wb1xV-F7tuUzCSZqcHpEpmUiXzL1XK4OW64w0ZWdw5wc73q8EwRTCHK8HrDJ6MirD5VS1jIHfVZKB2VGSnLbtvuvlFIvImcNdoqdnT_9H6Z3CHEQCLYWyVeA57JB__Am7ZH1fzYXkAN-VMHSQjoeunX8e_AU3rGck |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimization+of+Phage-Antibiotic+Combinations+against+Staphylococcus+aureus+Biofilms&rft.jtitle=Microbiology+spectrum&rft.au=Kebriaei%2C+Razieh&rft.au=Lehman%2C+Susan+M.&rft.au=Shah%2C+Rahi+M.&rft.au=Stamper%2C+Kyle+C.&rft.date=2023-06-15&rft.pub=American+Society+for+Microbiology&rft.eissn=2165-0497&rft_id=info:doi/10.1128%2Fspectrum.04918-22&rft.externalDocID=04918-22 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2165-0497&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2165-0497&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2165-0497&client=summon |